ABC-02: What the Biliary Tract Cancer Trial Found

A cancer with no standard treatment

Before 2010, someone with advanced cancer of the bile ducts or gallbladder faced a strange gap. There was no agreed first chemotherapy. Different centers used different drugs, chosen from small studies, and nobody could say which was better because no adequately sized trial had compared them.

The published report of ABC-02 opens with that fact: there is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer.

Where these cancers start

Bile is made in the liver and carried through a branching system of ducts to the gallbladder, where it is stored, and then to the small intestine, where it helps digest fat.

Cancer can start anywhere along that route. Cholangiocarcinoma arises in the bile ducts, either inside the liver or outside it. Gallbladder cancer arises in the gallbladder itself. Ampullary cancer arises where the bile duct and pancreatic duct meet and empty into the intestine.

These are separate diseases with different surgery and different outlooks. What they share is the drainage system, and it is that shared plumbing that produces the symptom most of them present with.

Trial at a glance

Field	Detail
Trial	ABC-02
Registry number	NCT00262769
Phase	3, extended from a randomized phase 2 of 86 patients
Participants	410
Population	Locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer
Comparison	Cisplatin plus gemcitabine (204 patients) vs gemcitabine alone (206)
Duration	Up to 24 weeks
Main measure	Overall survival

What the trial found

Median overall survival was 11.7 months with cisplatin plus gemcitabine and 8.1 months with gemcitabine alone. The hazard ratio was 0.64, with a 95% confidence interval of 0.52 to 0.80 and p<0.001 — meaning the risk of dying at any point in time was about 36% lower on the two-drug combination.

This is a survival result, not a surrogate. That distinction is worth pausing on, because most cancer trials report time before the cancer grows and leave survival to a later analysis. Here survival was the primary endpoint, median follow-up was 8.2 months, and 327 of the 410 participants had already died — so the estimate was mature rather than provisional.

Time before the cancer grew again was also longer: a median of 8.0 months against 5.0 months, p<0.001. The tumor control rate was 81.4% against 71.8%, p=0.049.

Adding a second drug did not add much harm. Side effects were similar between the groups, apart from more neutropenia — low counts of the white cells that fight bacteria — in the combination group. The number of infections associated with that neutropenia was similar in both.

When to get checked

Biliary tract cancers are uncommon and there is no screening test for them. They are found when someone reports symptoms. See a doctor promptly about:

• Yellowing of the skin or the whites of the eyes.
• Itching all over, sometimes before any yellowing appears, caused by bile salts building up in the skin.
• Urine that has turned dark and stools that have turned pale and greasy.
• A steady ache under the right ribs.
• Weight loss and appetite loss without an explanation.
• Fever with any of the above, which can mean an infected, blocked duct and needs same-day attention.

The combination of painless jaundice with itching is the classic presentation, and it should never be watched for a few weeks to see what happens. Our page on liver cancer covers related conditions of the same region.

Numbers, and why they are hard to quote here

SEER, the federal cancer surveillance program, groups liver cancer together with cancer of the bile ducts inside the liver. For that combined group, the projection of about 42,340 new US cases in 2026 and about 30,980 deaths comes from the American Cancer Society and is reproduced on SEER's page; five-year relative survival of 21.9% and a median age at diagnosis of 68 are SEER's own measurements.

That grouping does not map cleanly onto what ABC-02 studied. Gallbladder and ampullary cancers sit elsewhere in the registry, and hepatocellular carcinoma — the common liver cancer — dominates the combined figure. So treat those numbers as background about a region of the body, not as a survival estimate for biliary tract cancer.

Whatever the source, registry figures are averages across large groups diagnosed years ago. They describe populations, not people.

What to keep in perspective

• Median survival was still under a year in the better arm. This trial improved a poor outcome. It did not cure anyone.
• Three different cancers were pooled — bile duct, gallbladder, and ampullary. The trial cannot say how much each type gained.
• The control arm, gemcitabine alone, is not the standard today, so the comparison no longer describes a live clinical choice.
• The regimen has since been built on rather than replaced. Immunotherapy is now added to this same chemotherapy backbone on the basis of later trials, so the current standard is not what ABC-02 tested.
• Participants met specific entry criteria and were well enough to enroll, so results may not carry over to everyone with these cancers.

Questions worth asking

• Exactly which biliary tract cancer is this, and where in the system did it start?
• Has the tumor had molecular testing, and does anything in it point to a targeted option?
• Is a stent needed to relieve the blockage before chemotherapy starts?

Our explainer on what standard of care means in a trial covers how a control arm is chosen and why it dates.

Sources

• N Engl J Med 2010: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02), PMID 20375404 — record retrieved via NCBI eutils
• ClinicalTrials.gov API v2 record for NCT00262769
• NCI PDQ: Bile Duct Cancer (Cholangiocarcinoma) Treatment (Health Professional Version)
• NCI SEER Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.